Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Samantha Budd Haeberlein, Paul Aisen, Frederik Barkhof, +21

The Journal of Prevention of Alzheimer s Disease

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

Stephen Salloway, Spyros Chalkias, Frederik Barkhof, +11

JAMA Neurology

Trial of Cinpanemab in Early Parkinson’s Disease

Anthony E. Lang, Andrew Siderowf, Eric A. Macklin, +23

New England Journal of Medicine

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian, +21

The Lancet Neurology

Dose Phase 1BTranslational MedicineClinical TrialsProgressive Supranuclear PalsyMedicine +1

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Tien Dam, Adam L. Boxer, Lawrence I. Golbe, +17

Nature Medicine

RheumatologyProgressive Supranuclear PalsyPlacebo-controlled TrialPhase 2Medicine +1

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Susanna Eketjäll, Juliette Janson, Karin Kaspersson, +7

Journal of Alzheimer s Disease

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

Gvido Cebers, Robert Alexander, Samantha Budd Haeberlein, +10

Journal of Alzheimer s Disease

Healthy SubjectsNeurochemical BiomarkersPharmacotherapyAlzheimer ’Geriatric Neurology +16

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

Samantha Budd Haeberlein, John O’Gorman, Ping-Chun Chiao, +9

PubMed

Amyloid βImmunologyNeurochemical BiomarkersAlzheimer's DiseaseEarly Alzheimer +16

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease

Amanda Edwards, Jessica Collins, Candice Junge, +14

JAMA Neurology

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

Samantha Budd Haeberlein, Christian von Hehn, Ying Tian, +13

Alzheimer s & Dementia

Neurochemical BiomarkersEarly Alzheimer ’Geriatric NeurologyAlzheimer's DiseaseNeurobiology Of Disease +21